Multi-omics profiling is feasible, accelerates precision oncology, and improves outcomes for advanced melanoma.

#Onco404 #Cancer #Kanser #PrecisionOncology #ClinicalTrials #TumorProfiling #MedSky #OncSky #ASCO2025

✅ PFS: 6.04 months (overall palliative), 5.35 months (≥3rd-line therapy).
☑️ Outperformed non-TuPro matched cohorts: 64.7% DCR (TuPro) vs. 23.5% (non-TuPro) in ≥3rd-line patients.
✅ Cost-effective: 1.8x higher than standard NGS but enabled highly individualized therapies.

📊 Key Findings
✅ In 75% of cases, TuPro-based data (beyond standard NGS) was judged useful by the MTB for treatment recommendations. 54 distinct markers informed decisions.
☑️ Beyond SOC patients (n=37) achieved 38% ORR and 54% DCR - remarkable for refractory cases!

☑️ KRAS G12C ctDNA negativity at C1D8 → mPFS 7.26 vs 4.01 months
✅ ATM mutations reduced sotorasib benefit vs docetaxel (mPFS: 4.17 vs 8.25 months).

💡 These biomarkers enable precision patient selection and identify candidates for combination therapies. TTF-1 IHC may guide frontline decisions.

☑️ TTF-1 low vs TTF-1 high - ORR: 4.17% vs 42.1% ; mPFS: 2.76 vs 8.11 months (HR 0.23); mOS: 4.47 vs 16 months.
✅ Integration of NRF2 activation status and TTF-1 expression enabled robust partitioning of patients into favorable (~70%), intermediate (~13%) and poor (~17%) prognostic groups.

#Onco404

📊 Key Findings
☑️ KEAP1 co-mutations were correlated with significantly shorter PFS and OS on sotorasib.
✅ NRF2 activation (often linked to KEAP1 mutations) was also associated with inferior outcomes. mPFS: 2.73 vs 7.75 months (NRF2 low)

#Onco404 #Cancer #Kanser #AkciğerKanseri #MedSky #OncSky

❌ No significant differences in quality of life, feeling "heard/understood," or late hospice referrals.
✅ This scalable EHR-based strategy addressed clinician barriers, increased PC access without overburdening workflows, and offers a pragmatic solution for resource-limited settings.

#Onco404

📊 Key Findings
✅ 43.9% (intervention) vs. 8.3% (control) completed PC consults (adjusted OR: 8.9) ⤴️
☑️ Systemic therapy within 14 days of death was lower in the intervention group (6.5%) compared to control (16.1%; AOR 0.3).

#Onco404 #Cancer #Kanser #Hospice #PalliativeCare #MedSky #OncSky

Timely and comprehensive HRQoL data is vital for integrating patient experiences into clinical and regulatory decision-making.

#Onco404 #Cancer #Kanser #Oncology #ClinicalTrials #FDA #QoL #HRQoL #MedSky #OncSky #PatientReportedOutcomes

📊 HRQoL improved in 43% of trials but worsened in 4%, all linked to SEP-based approvals
⚠️ Reporting hasn’t improved since 2015. Delays mean doctors and patients often wait 6+ months
⚠️ Median latency for reporting was 1.1 months post-approval, but a quarter took over a year

#Onco404 #Cancer #Kanser

📊 Key Findings
📉 50% of trials reported HRQoL data, but only 42% had it available by FDA approval.
📉 79% of approvals relied on surrogate endpoints, yet only 18% of these showed improved HRQoL.
💊 Trials with survival (OS) endpoints: 70% reported HRQoL vs. 45% for SEPs.

#Onco404 #Cancer #Kanser

☑️ Trabectedin showed a higher frequency of grade ≥3 adverse events (AEs), serious AEs, and serious adverse drug reactions.

Trabectedin did not improve survival vs. standard chemo and had a worse safety profile. No subgroup (BRCA status, prior PARPi use) benefited more from trabectedin.

#Onco404

📊 Key Findings
✅ Median overall survival (OS): 15.8 months (arm A: trabectedin) vs. 17.9 months (arm B: control).
☑️ Median progression-free survival (PFS): 4.9 vs. 4.4 months.
✅ ORR was 17.1% (arm A) vs. 21.4% (arm B), with comparable median DoR (5.62 vs. 5.66 months).

#Onco404 #MedSky #OncSky